Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Рынки
Скринер
Новости
О нас

Home

CERS

(CERS)

NGM – Цена в реальном времени. Валюта: USD

1.78

-0.05 (-2.73%)

При закрытии: Mar 27, 2026, 4:00 PM EDT

1.78

0.00 (0.00%)

После закрытия: Mar 27, 2026, 7:23 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Видео

No Data

There is no data to display

Пресс-релизы

Cerus Appoints Vivek Jayaraman as President and Chief Executive Officer

Cerus Appoints Vivek Jayaraman as President and Chief Executive Officer

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced that Vivek Jayaraman, Cerus' chief operating officer, will be promoted to president and chief executive officer, effective July 1, 2026. William “Obi” Greenman will become executive chairman of the board of directors. At the time of his appointment, Mr. Jayaraman will join the Board of Directors. “Following a thorough succession planning process, this transition represents a natural step as we prepare for the nex.

Cerus Corporation Announces Full-Year and Fourth Quarter 2025 Financial Results

Cerus Corporation Announces Full-Year and Fourth Quarter 2025 Financial Results

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today financial results for its full year and fourth quarter ended December 31, 2025. “Our strong 2025 results reflect our disciplined execution, as we continued to deliver on our mission of safeguarding the world's blood supply. This past year, we achieved our highest annual kit shipments, enabling an estimated 600,000 patients worldwide to receive INTERCEPT-treated blood components,” said William “Obi” Greenman, Ceru.

Cerus Corporation to Participate in the TD Cowen 46th Annual Health Care Conference

Cerus Corporation to Participate in the TD Cowen 46th Annual Health Care Conference

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that members of the Company's management are scheduled to present at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 10:30 a.m. EST. A live webcast of the fireside chat will be accessible through the Investor Relations page of the Cerus website at http://www.cerus.com/ir. A replay will be available for 90 days after the event. ABOUT CERUS Cerus Corporation is dedicated solely to safe.

DRK Blood Donation Service Baden-Württemberg – Hessen Starts INITIATE Study to Evaluate Pathogen-Inactivated Platelet Concentrates Treated with Cerus' INTERCEPT™ Blood System in Routine Clinical Practice

DRK Blood Donation Service Baden-Württemberg – Hessen Starts INITIATE Study to Evaluate Pathogen-Inactivated Platelet Concentrates Treated with Cerus' INTERCEPT™ Blood System in Routine Clinical Practice

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced the start of the INITIATE study by the German Red Cross Blood Donation Service Baden-Württemberg – Hessen and its subsidiary organization, the German Red Cross Blood Donation Service North-East. The prospective, multicenter, non-interventional safety study, sponsored by DRK Blood Donation Service Baden-Württemberg-Hessen, is the first of its kind in Germany to evaluate the routine use of pathogen-inactivated plat.